AstraZeneca gains rights to Almirall’s respiratory franchise
As part of the deal, AstraZeneca agreed to pay Almirall about $875m of initial consideration, and up to $1.22bn in development, launch and sales-related milestones. The acquisition gives
GSK has entered an exclusive strategic partnership with SBP Group, via its subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ), to expedite the launch of bepirovirsen for chronic hepatitis B (CHB) patients in mainland China.
AVP-825 is an investigational drug-device combination product developed by OptiNose which uses OptiNose’s patented Bi-Directional Breath Powered technology to deliver a low dose of sumatriptan powder into the
In addition, the USACC has contracted for clinical evaluation of the VesiculoVax Zaire-Ebola virus vaccine to meet the current outbreak in West Africa. The $9.5 million award has
These waivers are applicable to current or pending New Drug Applications (NDAs) as well as successor products, including those with abuse-deterrent properties and associated labeling claims. In connection